文献速递神经肌肉病

使用全身脂肪参考MRI对FSHD进行定量肌肉分析:用于纵向和横断面分析的复合评分

Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis.
PubMed 文献 · Neurology · 2022-06-24

本研究纳入17例基因确诊的FSHD1患者,在6个中心间隔4-12周进行两次全身肌肉骨骼MRI,分析肌肉脂肪浸润、脂肪分数和瘦肌肉体积。功能复合评分与定时起立行走等评估呈中至强相关,全身复合评分变异度低,提示其可能作为临床试验中评估疾病变化的影像生物标志物。

要点

  • 全身肌肉骨骼MRI复合评分可捕捉FSHD1疾病异质性并与功能评估相关。
  • 功能复合评分与TUG、FSHD-TUG和RWS呈中至强相关。
  • 全身复合评分变异度低,可能用于治疗性临床试验中评估变化。

核心结论

  • 全身肌肉骨骼MRI方案及复合评分可捕捉FSHD疾病异质性,功能复合评分与FSHD相关临床终点稳健相关,全身复合评分的稳定性显示其可能用于治疗性临床试验中评估变化。

研究设计与样本

  • 纳入年龄18-65岁、基因确诊FSHD1、临床严重度2至4(Ricci量表,范围0-5)、且至少一块短tau反转恢复阳性下肢肌肉适合针吸活检的参与者,在6个中心入组,间隔4-12周进行两次成像。
  • 对双侧肩、近端臂、躯干和腿的18块(共36块)肌肉进行自动图谱分割后手动验证,分析肌肉脂肪浸润、肌肉脂肪分数和瘦肌肉体积。
  • 开发了包含进展风险最高肌肉的全身复合评分,以及与定时起立行走、FSHD-TUG和可达工作空间等功能结局相关的功能横断面复合评分。

主要发现

  • 17例参与者入组,16例在52天(范围36-85天)完成随访MRI。
  • 功能横断面复合评分(MFF和MFI)与TUG(ρ=0.71,ρ=0.83)、FSHD-TUG(ρ=0.73,ρ=0.73)和RWS(左臂:ρ=-0.71,ρ=-0.53;右臂:ρ=-0.61,ρ=-0.65)呈中至强相关。
  • 全身复合评分变异度:LMVtot的变异系数为1.9%和3.4%;MFFtot的受试者内标准差为0.5%和1.5%;MFItot的受试者内标准差在正常肌肉和中间肌肉分别为0.3%和0.4%。
  • 中间肌肉(MFI ≥0.10;MFF <0.50)的变异系数和受试者内标准差高于正常肌肉(MFI <0.10,MFF <0.50)。

关键数值与推荐

  • 本研究提供II级证据,表明定量全身肌肉骨骼MRI表现与使用既定功能评估测量的FSHD1严重度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Facioscapulohumeral muscular dystrophy (FSHD) is a rare, debilitating disease characterized by progressive muscle weakness. MRI is a sensitive assessment of disease severity and progression. We developed a quantitative whole-body (WB) musculoskeletal MRI (WB-MSK-MRI) protocol analyzing muscles in their entirety. This study aimed to assess WB-MSK-MRI as a potential imaging biomarker providing reliable measurements of muscle health that capture disease heterogeneity and clinically meaningful composite assessments correlating with severity and more responsive to change in clinical trials. METHODS: Participants aged 18-65 years, with genetically confirmed FSHD1, clinical severity 2 to 4 (Ricci scale, range 0-5), and ≥1 short tau inversion recovery-positive lower extremity muscle eligible for needle biopsy, enrolled at 6 sites and were imaged twice 4-12 weeks apart. Volumetric analysis of muscle fat infiltration (MFI), muscle fat fraction (MFF), and lean muscle volume (LMV) in 18 (36 total) muscles from bilateral shoulder, proximal arm, trunk, and legs was performed after automated atlas-based segmentation, followed by manual verification. A WB composite score, including muscles at highest risk for progression, and functional cross-sectional composites for correlation with relevant functional outcomes including timed up and go (TUG), FSHD-TUG, and reachable workspace (RWS), were developed. RESULTS: Seventeen participants enrolled in this study; 16 follow-up MRIs were performed at 52 days (range 36-85 days). Functional cross-sectional composites (MFF and MFI) showed moderate to strong correlations: TUG (ρ = 0.71, ρ = 0.83), FSHD-TUG (ρ = 0.73, ρ = 0.73), and RWS (left arm: ρ = -0.71, ρ = -0.53; right arm: ρ = -0.61, ρ = -0.65). WB composite variability: LMVtot, coefficient of variation (CV) 1.9% and 3.4%; MFFtot, within-subject SD (Sw) 0.5% and 1.5%; and MFItot (Sw), 0.3% and 0.4% for normal and intermediate muscles, respectively. CV and Sw were higher in intermediate (MFI ≥0.10; MFF <0.50) than in normal (MFI <0.10, MFF <0.50) muscles. DISCUSSION: We developed a WB-MSK-MRI protocol and composite measures that capture disease heterogeneity and assess muscle involvement as it correlates with FSHD-relevant clinical endpoints. Functional composites robustly correlate with functional assessments. Stability of the WB composite shows that it could be an assessment of change in therapeutic clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that quantitative WB-MSK-MRI findings associate with FSHD1 severity measured using established functional assessments.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mellion ML, Widholm P, Karlsson M, et al. Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis. Neurology. 2022. PMID: 35750498. doi:10.1212/WNL.0000000000200757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。